Drugs / LANDIPIRDINE
LANDIPIRDINE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02258152 | Dec 2014 → Oct 2017 | Parkinson disease | Biotie Therapies Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LANDIPIRDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1082508 ↗ |
| Known as | Landipirdina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1082508 ↗ |
| Known as | R0-5025181 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1082508 ↗ |
| Known as | R0-5025181-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1082508 ↗ |
| Known as | RO5025181 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1082508 ↗ |
| Known as | RO5025181-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1082508 ↗ |
| Known as | SYN120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02258152 ↗ |
| Action | Inhibit | “SYN120 is a dual serotonin receptor (5-HT6/5-HT2A) antagonist hypothesized to improve cognition and psychiatric symptoms.” PMID 37532622 ↗ Jul 2023 |
| Modality | Small molecule | — CHEMBL1082508 ↗ |
| Route | Oral | “eligible patients were randomized to oral SYN120 (100 mg/day) or placebo.” PMID 37532622 ↗ Jul 2023 |